Nocturnal aspects of narcolepsy with cataplexy

Plazzi, Giuseppe; Serra, Leonardo; Ferri, Raffaele

doi:10.1016/j.smrv.2007.08.010

Cited by 85 publications

(47 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[13][14][15] Thus, DNS may represent an additional characteristic of narcolepsy to be considered as part of a pentad of symptoms rather than EDS and the triad of auxiliary symptoms.…”

Section: Resultsmentioning

confidence: 99%

“…10,13,39 Aside from the short sleep latency, it is also characterized by an inability to stay asleep. ing sleep.…”

Section: Nighttime Sleep In Narcolepsymentioning

confidence: 99%

“…Nevertheless, DNS remains a symptom that typically goes untreated. 7,9,11,13 Current guidelines from the AASM endorse "control [ling] nocturnal symptoms of disrupted sleep…when present and troublesome in patients with narcolepsy," 7 whereas guidelines from the EFNS note that improvements in DNS are achievable, but the guidelines do not provide a specific treatment recommendation. 9 Therefore, studies are needed that evaluate objective and patient-reported effects of various therapies on the treatment of DNS.…”

Section: Treatment Of Dns In Narcolepsymentioning

confidence: 99%

See 2 more Smart Citations

Disrupted Nighttime Sleep in Narcolepsy

Roth

Dauvilliers

Mignot

et al. 2013

Journal of Clinical Sleep Medicine

172

View full text Add to dashboard Cite

show abstract

“…[13][14][15] Thus, DNS may represent an additional characteristic of narcolepsy to be considered as part of a pentad of symptoms rather than EDS and the triad of auxiliary symptoms.…”

Section: Resultsmentioning

confidence: 99%

“…10,13,39 Aside from the short sleep latency, it is also characterized by an inability to stay asleep. ing sleep.…”

Section: Nighttime Sleep In Narcolepsymentioning

confidence: 99%

Section: Treatment Of Dns In Narcolepsymentioning

confidence: 99%

See 1 more Smart Citation

Disrupted Nighttime Sleep in Narcolepsy

Roth

Dauvilliers

Mignot

et al. 2013

Journal of Clinical Sleep Medicine

172

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…This disorder is also associated with the gene marker, human leukocyte antigen (HLA)-DQB1*0602 [11]. This disease is also considered to be associated with a higher expression of sleep-disordered breathing [12,13]. Our primary hypothesis was that an impaired chemoresponsiveness would be present in narcolepsy-cataplexy patients who are uniformly HLADQB1*0602 positive and have low hypocretin levels ,110 pg?mL -1 in comparison to control subjects without disease or cataplexy or the HLA marker who have normal levels of hypocretin (over 99% .110 pg?mL -1 ) [9].…”

mentioning

confidence: 99%

Ventilatory chemoresponsiveness, narcolepsy–cataplexy and human leukocyte antigen DQB1*0602 status

Han¹,

Mignot²,

Wei³

et al. 2010

Eur Respir J

View full text Add to dashboard Cite

We hypothesised that hypocretin (orexin) plays a role in the determination of ventilatory chemosensitivity. 130 patients with narcolepsy-cataplexy (mean¡SD age 20¡10 yrs, 69% male) and 117 controls (22¡6.9 yrs, 62% male) were recruited and tested for human leukocyte antigen (HLA)-DQB1*0602 status, hyperoxia hypercapnic (change in minute ventilation (DV9E)/carbon dioxide tension (DPCO 2 ) L?min KEYWORDS: Chemoresponsiveness, human leukocyte antigen DQB1, hypercapnia, hypoxia, narcolepsy H ypoxic and hypercapnic sensing are processed through neuromuscular circuits resulting in an increase or decrease of tidal volume, respiratory frequency and minute ventilation (V9E). Such chemosensory reflexes operate to influence sleep apnoea, chronic obstructive pulmonary disease (COPD), heart failure, and acute adaptation to high altitude [1]. A variation in chemosensitivity across various inbred rodent strains and familial clustering of ventilatory traits in humans provides a strong rationale for gene and protein isolation efforts to unravel molecular mechanisms for these traits operating in health and disease [2].Hypocretin (orexin) is a hypothalamic neurotransmitter, which, when given intracerebroventricularly in mice, promotes both wakefulness and ventilation [3,4]. Both hypocretin knockout and hypocretin neuron-ablated mice show attenuation of respiratory excitation during fightor-flight responses [5]. Particular to chemoresponsiveness, hypocretin/orexin knockout mice have attenuated hypercapnic ventilatory responses [6]; supplementation of hypocretin-1 or -2 partially restores an attenuated response to hypercapnia, while administration of hypocretin receptor-1 antagonist will reduce hypercapnic responsiveness in wild type mice [7]. Post-hypoxic long-term facilitation, a physiological feature that is presumed to reduce sleep apnoea, is absent in hypocretin/orexin knockout mice [8].The human model of hypocretin deficiency is narcolepsy with cataplexy [9,10]. This disorder is also associated with the gene marker, human leukocyte antigen (HLA)-DQB1*0602 [11]. This disease is also considered to be associated with a higher expression of sleep-disordered breathing [12,13]. Our primary hypothesis was that an impaired chemoresponsiveness would be present

show abstract

Sleep Cycles

Manber¹

2010

The Corsini Encyclopedia of Psychology

View full text Add to dashboard Cite

Human sleep changes across the night in a cyclic pattern. Each sleep cycle begins with non‐rapid eye movement (NREM) sleep and ends with rapid eye movement (REM) sleep. The cycling frequency is approximately 90 minutes but shorter than this during the first year of life. The number of sleep cycles depends on the duration of sleep. An average young adult who sleeps well has between 5 and 6 sleep cycles during a typical night's sleep. The organization of sleep during the first year of life differs substantially and depends on brain maturation during this early stage of human development.

show abstract

Nocturnal aspects of narcolepsy with cataplexy

Cited by 85 publications

References 135 publications

Disrupted Nighttime Sleep in Narcolepsy

Disrupted Nighttime Sleep in Narcolepsy

Ventilatory chemoresponsiveness, narcolepsy–cataplexy and human leukocyte antigen DQB1*0602 status

Sleep Cycles

Contact Info

Product

Resources

About